Boeing Co vs Inovio Pharmaceuticals Inc — how do they compare? Boeing Co trades at $233.82 (market cap $184.35B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Boeing Co is far larger — about 2346.9× Inovio Pharmaceuticals Inc's market cap, and Boeing Co pays a 0.03% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BA | INO | |
|---|---|---|
Market Cap | $184.35B | $78.55M |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $2.87 |
52-Week Low | $179.12 | $0.66 |
Enterprise Value | $210.23B | $49.56M |
Dividend Yield | 0.03% | — |
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $232.79, down 0.7% on the day, with a bullish technical signal supported by moving averages. The company reported revenue of $89.46B in 2025, swinging to a net income of $2.24B, and recent news highlights its strategic sale of non-core aviation technology units to Archer Aviation to sharpen focus on core aerospace and defense operations.
The outlook is positive with a consensus price target of $280.83, though high valuation ratios and volatile cash flows pose risks. Earnings momentum is mixed, with a recent Q2 2026 EPS miss, but analyst sentiment remains strongly bullish with 67% buy ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →